2,5-二氯-3-溴吡啶 | 138006-41-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,5-二氯-3-溴吡啶
• 中文别名: 2,5-二氯-3-溴；3-溴-,5-二氯吡啶；3-溴-2,5-二氯吡啶
• 英文名称: 3-bromo-2,5-dichloropyridine
• CAS: 138006-41-4
• 化学式: C₅H₂BrCl₂N
• mdl: MFCD06659484
• 分子量: 226.888
• InChiKey: CDBHWRZEXFQNBI-UHFFFAOYSA-N

物化性质

• 熔点：
  38-40°C
• 沸点：
  195-198C
• 密度：
  1,199g/cm
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  如果遵照规格使用和储存，则不会分解，未有已知危险反应。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 危险品运输编号：
  UN2811
• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Bromo-2,5-dichloropyridine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
3-Bromo-2,5-dichloropyridine
Ingredient name:
CAS number: 138006-41-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H2BrCl2N
Molecular weight: 226.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (3-Bromo-2,5-dichloropyridine)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,5-二氯-3-溴吡啶 在 正丁基锂 、 Celite 、 potassium tert-butylate 、 四丁基氟化铵 、 sodium hydrogensulfite 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 、 formamide 、 叔丁醇 为溶剂， 反应 8.0h， 生成 (2'R,4'S)-6'chloro-2',3'-dihydro-2'-methylspiropyridine>-2,5-dione
  参考文献：
  名称：

  2,3-Pyridine annulation. The enantioselective synthesis of an aldose reductase inhibitor

  摘要：

  DOI：

  10.1021/jo00032a060
• 作为产物：
  描述：

  3-溴-5-氯-2-羟基吡啶 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以81.76 g (89%)的产率得到2,5-二氯-3-溴吡啶
  参考文献：
  名称：

  6-chloro-3,4-dihydro-pyrano [2,3-b]pyridines having the R configuration

  摘要：

  本发明涉及用于制备螺环杂异唑酮的过程和中间体。后者化合物可用作醛糖还原酶抑制剂。

  公开号：

  US05068333A1

文献信息

• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• 芳氧基苯胺基丙酸酯类化合物及其作为除草剂的应用
  申请人：长江大学

  公开号：CN105439945A

  公开（公告）日：2016-03-30

  芳氧基苯胺基丙酸酯类化合物，包括如下通式(I)表示的结构：其中，Ar为杂芳环或者稠杂环；杂芳环为稠杂环为R1、R2、R3、R4为H、卤素、硝基、甲氧基、甲基、甲酸甲酯基、氰基或三卤甲基中的一种或者几种；R5为H、C1～C4的直链或者支链的烷基，烷基上的氢被羟基、羧基、巯基、氨基、胍基、苯基取代；R6为甲基、乙基、丁基、中的一种；其优点是：此结构化合物，能保持芳氧苯氧丙酸酯类除草剂高效、速效、不易产生抗性等优点；同时可设计分子中的氨基酸官能团作为掺假氨基酸，抑制植物本身蛋白质的生物合成，对所有杂草具有防除作用。
• [EN] PHENOXY ACETIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE PHÉNOXYACÉTIQUE
  申请人：MERCK SERONO SA

  公开号：WO2010092043A1

  公开（公告）日：2010-08-19

  The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.

  本发明提供了用于治疗与CRTH2相关的疾病和疾病（包括哮喘、特应性皮炎和炎症性皮肤病）的Formula（I）的苯氧乙酸衍生物。
• Iron‐Catalyzed Radical Activation Mechanism for Denitrogenative Rearrangement Over C(sp ³ )–H Amination
  作者：Satyajit Roy、Sandip Kumar Das、Hillol Khatua、Subrata Das、Krishna Nand Singh、Buddhadeb Chattopadhyay

  DOI：10.1002/anie.202014950

  日期：2021.4.12

  An iron‐catalyzed denitrogenative rearrangement of 1,2,3,4‐tetrazole is developed over the competitive C(sp3)–H amination. This catalytic rearrangement reaction follows an unprecedented metalloradical activation mechanism. Employing the developed method, a wide number of complex‐N‐heterocyclic product classes have been accessed. The synthetic utility of this radical activation method is showcased with

  在竞争性的C（sp 3）–H胺化反应中，形成了铁催化的1,2,3,4-四唑脱氮重排。这种催化重排反应遵循前所未有的金属铁活化机理。使用已开发的方法，已经访问了许多复杂的N杂环产品类别。这种自由基活化方法的合成实用性通过生物活性分子的短合成得以展示。总的来说，这一发现强调了自由基激活策略的进展，该策略应在药物化学，药物发现和天然产物合成研究的角度得到广泛应用。
• Fused Bicyclic Kinase Inhibitors
  申请人：Mulvihill Mark J.

  公开号：US20110281888A1

  公开（公告）日：2011-11-17

  Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

  公式I的化合物如下所示并在此定义： 其药用可接受盐、合成、中间体、配方以及使用其进行疾病治疗的方法，包括治疗癌症，如至少部分由RON、MET或ALK驱动的肿瘤。本摘要不限制该发明。